Skip to main content

Table 3 Dose Escalation Regression Estimates – Inflixim ab and Etanercept Dependent Variables (Increase in dose for Inflixim ab or Etanercept 1 = yes, 0 = no)

From: Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

Parameter Level Estimate Odds-Ratio Transformed Odds Ratio Conditional Probability p-value
Intercept   -0.3129 0.73 n.a. n.a. 0.1702
HMO Yes -0.2246 0.80 1.00 0.37 0.0826
  No 0.0000 1.00 1.25 0.42  
Treatment Inflixim ab 0.0000 1.00 6.38 0.42  
  Etanercept -1.8529 0.16 1.00 0.10 <.0001
Region West 0.0000 1.00 1.00 0.42  
  Northeast 0.6505 1.92 1.92 0.58 0.0215
  Midwest 0.6382 1.89 1.89 0.58 0.0063
  South 0.6252 1.87 1.87 0.58 0.0102
Pre-Period Non RA Related Costs ('000s) Yes 0.0350 1.04 1.04 0.43 0.0185
  No   1.00 1.00 0.42  
Crohn's Disease Yes -0.7328 0.48 1.00 0.26 0.0477
  No 0.0000 1.00 2.08 0.42  
Cox-IIs Yes 0.3064 1.36 1.36 0.50 0.0175
  No 0.0000 1.00 1.00 0.42